Context Therapeutics (CNTX) announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer, CMO, effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company’s Board of Directors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
- Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
- Context Therapeutics CMO Claudio Dansky Ullmann to depart
- Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
- Context Therapeutics presents preclinical data on CT-95
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue